Loading...
XKRX028300
Market cap5.90bUSD
Dec 20, Last price  
69,600.00KRW
1D
-0.85%
1Q
-22.41%
Jan 2017
429.28%
Name

HLB Inc

Chart & Performance

D1W1MN
XKRX:028300 chart
P/E
—
P/S
198.76
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
4.89%
Rev. gr., 5y
3.46%
Revenues
42.90b
-76.13%
51,641,814,94020,807,717,81037,185,747,89038,460,683,50730,138,866,81423,006,912,16736,185,983,41638,420,748,24556,177,400,69669,825,991,454179,707,913,11242,900,561,190
Net income
-189.08b
L+141.92%
-5,250,075,860-6,780,075,560-1,481,228,83012,639,604,648-13,214,518,061-16,529,938,42225,342,858,133-44,386,487,974-80,093,074,231-98,125,465,674-78,158,868,867-189,079,377,010
CFO
-111.63b
L+80.59%
-891,716,350-4,084,405,290-3,971,900,680527,191,358-10,151,013,868-19,080,875,878-29,162,869,869-48,656,702,381-56,513,635,182-54,765,398,832-61,816,035,433-111,631,653,900
Earnings
Feb 12, 2025

Profile

HLB Co., Ltd. manufactures pharmaceutical products, and builds ships. It manufactures and sells various types of lifeboats for marine plants, drill ships, and cruise vessels in South Korea. The company offers conventional type lifeboats, free fall type lifeboats, and rescue boats. It also provides marine and yacht engines; hooks; RIB, patrol, fishing, aluminum, and leisure boats; fishery inspection ships; and safety goods, as well as lifeboat and davit inspection and repair services, service engineering training, and spare parts for lifeboats and davits. In addition, the company develops Riboseranib, a targeted anti-cancer agent; and Apilia that is used for the treatment for ovarian cancer. HLB Co., Ltd. was founded in 1975 and is headquartered in Ulsan, South Korea.
URL
http://www.hlbkorea.com/
IPO date
Jul 27, 1996
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
42,900,561
-76.13%
179,707,913
157.37%
69,825,991
24.30%
Cost of revenue
126,131,497
195,046,858
130,792,303
Unusual Expense (Income)
NOPBT
(83,230,936)
(15,338,945)
(60,966,312)
NOPBT Margin
Operating Taxes
(6,753,777)
10,192,611
1,157,396
Tax Rate
NOPAT
(76,477,160)
(25,531,556)
(62,123,708)
Net income
(189,079,377)
141.92%
(78,158,869)
-20.35%
(98,125,466)
22.51%
Dividends
Dividend yield
Proceeds from repurchase of equity
(4,077,751)
237,605,125
512,505
BB yield
0.07%
-7.80%
-0.01%
Debt
Debt current
30,867,671
116,164,006
22,437,256
Long-term debt
47,819,713
13,681,779
57,111,242
Deferred revenue
513,683
13,361,779
9,733,384
Other long-term liabilities
988,410
217,558
323,164
Net debt
(302,470,005)
(297,409,950)
(211,049,164)
Cash flow
Cash from operating activities
(111,631,654)
(61,816,035)
(54,765,399)
CAPEX
(7,058,823)
(12,627,000)
(6,140,959)
Cash from investing activities
25,534,919
(112,279,852)
(68,496,022)
Cash from financing activities
(3,048,694)
267,579,356
1,335,361
FCF
(29,671,476)
(90,955,792)
(83,689,987)
Balance
Cash
112,803,605
204,085,709
127,116,601
Long term investments
268,353,784
223,170,025
163,481,061
Excess cash
379,012,361
418,270,339
287,106,362
Stockholders' equity
99,262,646
(205,233,360)
(285,575,387)
Invested Capital
547,147,881
1,027,885,223
867,991,274
ROIC
ROCE
EV
Common stock shares outstanding
121,235
112,588
120,178
Price
50,700.00
87.45%
27,047.62
-22.28%
34,800.00
-24.76%
Market cap
6,146,635,845
101.84%
3,045,250,586
-27.19%
4,182,189,911
-26.89%
EV
5,902,530,437
2,808,885,294
4,047,371,793
EBITDA
(76,262,602)
986,704
(48,936,280)
EV/EBITDA
2,846.73
Interest
10,586,054
11,692,170
3,627,280
Interest/NOPBT